Biologics Hold Key to Important Treatments (Sen. Mike Enzi)

Yesterday the Health, Education, Labor and Pensions (HELP) Committee approved legislation yesterday that will allow the Food and Drug Administration (FDA) to approve follow-on biologics in an expedited way, while preserving incentives to develop new therapies, without compromising patient safety.

The “Biologics Price Competition and Innovation Act of 2007

I would like to thank my colleagues for their hard work on this issue, particularly Sen. Orrin Hatch (R-Utah), who has long been a leader in promoting affordable treatments and protecting patient safety. The bill our committee approved today builds on the legacy of the Hatch-Waxman generic drug bill, and I believe it strikes the right balance to be just as successful as that landmark legislation.

I introduced the “Biologics Price Competition and Innovation Act